Efectiv Nutrition has rolled out a teaser image for an upcoming supplement that is well worth teasing, especially since it is an industry first for its particular market. It wasn’t too long ago that the sports nutrition giant MuscleTech debuted the innovative DL-185 dileucine in its muscle-building and recovery-enhancing product Peptide 185. It is that superior leucine evolution that will be the center of attention of the upcoming Efectiv supplement that appears to be appropriately titled MPS 185.
DL-185, or dileucine, is a novel muscle-building ingredient featured in MuscleTech’s Peptide 185 supplement, and it is a leucine-to-leucine bond backed by impressive results in studies, demonstrating a 159% increase in muscle protein synthesis compared to placebo and a 60% increase over standard leucine. The key advantage of DL-185 lies in its enhanced bioavailability and uptake, which allows it to achieve results that are unattainable with regular leucine, even at higher doses.
We’re not sure about the dose of DL-185 Efectiv Nutrition plans on putting into MPS 185, although to ensure the great results that are promoted by the premium ingredient, we have to imagine it’ll be in and around what MuscleTech has in Peptide 185 at 2g a serving. The brand has an estimated time of arrival for MPS 185 of two weeks, so right near the end of the month, coming in capsule format and presumably standalone for versatility so it can be stacked with other like-minded products.
